OncoMatch/Clinical Trials/NCT05244239
Palliative Radiotherapy With Lurbinectedin in Patients With Extensive Stage Small Cell Lung Cancer
Is NCT05244239 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies Lurbinectedin for extensive stage lung small cell carcinoma.
Treatment: Lurbinectedin — This phase I trial aims to determine if it is safe to use palliative radiotherapy and lurbinectedin at the same time to treat small cell lung cancer that has spread outside of the chest and that has grown after being treated with chemotherapy (extensive stage). Lurbinectedin kills tumor cells by blocks a process called transcription that small cell lung cancer relies on to survive. It also damages the deoxyribonucleic acid (DNA) of tumor cells, which is similar to the way radiation kills tumor cells. Palliative radiotherapy is a routine medical treatment for patients who have lung cancer that has spread to other parts of the body (metastatic), and is used to relieve symptoms caused by cancer or to patients from developing symptoms. This trial may help doctors understand if treating patients with lurbinectedin and palliative radiotherapy at the same time would make them both work better than either one alone or if they could cause more side effects for patients when given together.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Disease stage
Required: Stage IV (AJCC v8)
Metastatic disease required
Patients with pathologically confirmed ES-SCLC who are receiving lurbinectedin or are candidates for lurbinectedin therapy after progression on first-line systemic therapy (either chemotherapy [platinum etoposide] or chemoimmunotherapy) at the discretion of the treating medical oncologist.
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Eastern Cooperative Oncology Group (ECOG) performance status =< 3
Prior therapy
Must have received: systemic therapy (platinum etoposide) — first-line
progression on first-line systemic therapy (either chemotherapy [platinum etoposide] or chemoimmunotherapy)
Lab requirements
Blood counts
ANC ≥ 1,500/cells/mm^3; Platelets ≥ 100,000/cells/mm^3; Hemoglobin > 7.0 g/dL
Liver function
Total Bilirubin ≤ 1.5 ULN; AST/ALT ≤ 3.0 x ULN (≤ 5.0x ULN for liver involvement); Alkaline phosphatase ≤ 2.5x ULN (≤ 5.0x with documented liver or bone metastases)
Absolute neutrophil count (ANC) ≥ 1,500/cells/mm^3; Platelets ≥ 100,000/cells/mm^3; Hemoglobin > 7.0 g/dL; Total Bilirubin ≤ 1.5 ULN; AST/ALT ≤ 3.0 x ULN (≤ 5.0x ULN for liver involvement); Alkaline phosphatase ≤ 2.5x ULN (≤ 5.0x with documented liver or bone metastases)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Emory University Hospital Midtown · Atlanta, Georgia
- Emory University · Atlanta, Georgia
- Emory Saint Joseph's Hospital · Atlanta, Georgia
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify